

## The ENTENTE Project presents the award winners of the Entente Life Sciences Investment Forum 2014

Brussels, 13<sup>th</sup> of October 2014 - The **Entente Life Sciences Investment Forum** took place **last Thursday, October 9<sup>th</sup>** in **Brussels, Belgium**. The event was organized by the Entente Project, and supported by the European Commission and EuropaBio.

The Life Sciences Investment Forum united 28 European early stage innovative companies, selected from a pool of around 100 companies, active in the health sector and seeking investment opportunities and international exposure. The selected companies pitched their innovation, developments and needs in front of an international jury consisting of around 50 venture capitalists, corporate investors, business angels, and other industry experts.

The award winners qualified to continue along the European Venture contest; a pan-European contest of venture events that gathers the best of each edition to join the European Venture Summit, Europe's largest venture capital match-making event, taking place on 8<sup>th</sup> and 9<sup>th</sup> of December 2014 in Düsseldorf, Germany.

Karine Baudin, VP Technology Transfer InsermTransfert, ENTENTE Project: *"Our project aims at reinforcing links and promoting transnational collaboration through networking activities among all stakeholders, sharing experience and best practices. We hope that this meeting will result in investment from venture capitalists and early investors into these companies and therefore will support the European competitiveness with the final aim of the development of innovative products in health."*

### **Below are the names of the 8 Award Winners of the Entente Life Sciences Investment Forum 2014:**

- **A2M Pharma** - Germany  
Neurology drug development spin-off from Schwarz Pharma
- **BC Platforms** - Finland  
BC Platforms is a leading innovator in the rapidly growing genomic data management markets. BC's clinical and genomic data integration and analysis platform is used by thousands of academic, healthcare and pharmaceutical professionals across the world.
- **CluePoints** – Belgium  
CluePoints is a Central Statistical Monitoring solution that has been designed and perfected over the last 10 years. It employs unique statistical algorithms to determine the quality, accuracy and integrity of clinical trial data.
- **Enterome** - France  
Microbiome Company
- **Curavac** – Belgium  
Therapeutic Vaccines for Autoimmune Diseases
- **EyeTechCare**- France  
EyeTechCare's proprietary ultrasound technology offers non-invasive treatment of glaucoma, the second largest cause for blindness. The product is CE marked and in early commercialization.



- **OncoLab Diagnostics GmbH** - Austria

Only a simple blood draw is enough to detect cancer! We focus on production and commercialisation of proprietary innovative technologies to diagnose cancer earlier, and to detect and analyse traces of cancer in the patient's body.

- **Quanta Fluid Solutions** – Great Britain

A pioneering UK-based medical devices company focusing on the development and commercialisation of a novel cartridge-based haemodialysis system.

You can view the list of presenting companies and their profile at the link:

[http://e-unlimited.com/events/view.aspx?events\\_pages\\_id=3021](http://e-unlimited.com/events/view.aspx?events_pages_id=3021)

You can view the full list of Jury Members and their biographies at the link:

[http://e-unlimited.com/events/view.aspx?events\\_pages\\_id=2932](http://e-unlimited.com/events/view.aspx?events_pages_id=2932)

Event Website: <http://www.entente-lifesciencesinvestmentforum.eu>

For information please contact Annalisa Gardella at: [annalisa@e-unlimited.com](mailto:annalisa@e-unlimited.com) or call at :+32 2 643 36 91

~~~

## Note to the editors

### About the European Venture Contest

The European Venture Contest finds, evaluates and awards the most promising entrepreneurs in the high technology sector by providing access to top-level international partners, advisors and financiers. The Contest reaches this year its 9th edition, and in the past years gathered over 800 companies and 600 venture capitalist and corporate investors from all over Europe. The top 100 companies awarded at the qualifier events will present in December at the European Venture Summit in front of an audience of 150 top European investors.

[www.e-unlimited.com/evc](http://www.e-unlimited.com/evc)

### About ENTENTE

The ENTENTE-Life Sciences Investment Forum is part of the ENTENTE project ([www.entente-health.eu](http://www.entente-health.eu)), which has received funding from the European Union's Seventh Programme for research, technological development and demonstration under grant agreement No 305128. ENTENTE is the first European network to boost knowledge transfer activity in health research among academic and public organisations and industrial counterpart. The project aims at reinforcing links and promoting transnational collaboration by achieving

4 main objectives:

- Networking activities among all stakeholders
- Sharing Experience and Best Practices; giving visibility to Success Stories
- Implementing an exchange programme for professionals of Technology Transfer in Health
- Formulating recommendations for enhancing knowledge transfer in health at European level



### **About EuropaBio**

EuropaBio is the European Association of BioIndustries. Its members are involved in research, development, testing, manufacturing and commercialisation of biotech products and processes in human and animal healthcare, diagnostics, bioinformatics, chemicals, crop protection, agriculture, food and environmental products and services. EuropaBio also counts a number of National Biotech Associations in its membership who in turn represents more than 1800 SMEs.